Alpha 2.0
Login Register
» Authors » S Christopher Jones

S Christopher Jones

Explore the profile of S Christopher Jones including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 295
Followers 0
Related Specialties
Pharmacology
Oncology
Toxicology
Top 10 Co-Authors
Afrouz Nayernama
Lynda MCCulley
Peter E Waldron
Susan J Bersoff-Matcha
Graca M Dores
Daniel Woronow
Connie Cheng
Michelle Nadeau Nguyen
Alfred Sorbello
Allen Brinker
Published In
Drug Saf
Am J Hematol
J Oncol Pharm Pract
Clin Infect Dis
Ann Pharmacother
Affiliations
Soon will be listed here.
Recent Articles
1.
Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature
Cheng C, Dores G, Nayernama A, Jones S, Rabik C
Pediatr Hematol Oncol . 2024 Aug; 41(7):519-529. PMID: 39194183
Multiple asparaginase products have been approved by the United States (US) Food and Drug Administration (FDA) for the treatment of acute lymphoblastic leukemia in pediatric and adult patients. Hepatic veno-occlusive...
2.
Using natural language processing to characterize and predict homeopathic product-associated adverse events in consumer reviews: comparison to reports to FDA Adverse Event Reporting System (FAERS)
Konkel K, Oner N, Ahmed A, Jones S, Berner E, Zengul F
J Am Med Inform Assoc . 2023 Oct; 31(1):70-78. PMID: 37847653
Objective: Apply natural language processing (NLP) to Amazon consumer reviews to identify adverse events (AEs) associated with unapproved over the counter (OTC) homeopathic drugs and compare findings with reports to...
3.
Varicella zoster virus reactivation reported with isatuximab use
Nadeau Nguyen M, Dores G, Nayernama A, Jones S
J Chemother . 2023 Oct; 36(3):198-201. PMID: 37800850
Isatuximab is a CD38-directed antibody indicated for the treatment of relapsed or refractory multiple myeloma. The Division of Pharmacovigilance at the U.S. Food and Drug Administration (FDA) reviewed case reports...
4.
Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration
Sullivan K, Dores G, Nayernama A, Prowell T, Pradhan S, Osgood C, et al.
JAMA Oncol . 2022 Aug; 8(10):1503-1505. PMID: 35980660
No abstract available.
5.
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults
Nadeau Nguyen M, Chambers W, Dores G, Nayernama A, Jones S
JAMA Oncol . 2022 Jun; 8(8):1209-1210. PMID: 35653128
No abstract available.
6.
Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System
Dores G, Nayernama A, Cheng C, Moureaud C, Jones S
Am J Hematol . 2022 Jan; 97(4):E129-E132. PMID: 34985778
No abstract available.
7.
Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series
Cotter S, Wong J, Gada N, Gill R, Jones S, Chai G, et al.
Drug Saf . 2021 Oct; 44(12):1365-1374. PMID: 34699023
Introduction: Emerging off-label medical uses of ketamine for the treatment of persistent conditions such as depression and chronic pain often require repeated administration. Cases reported by other countries suggest that...
8.
Pentosan associated retinal pigmentary changes: FDA's perspective on an emerging postmarketing safety finding
Lardieri A, Konkel K, MCCulley L, Jones S, Moeny D, Nguyen C, et al.
Int Urogynecol J . 2021 Sep; 32(11):2891-2897. PMID: 34505923
Introduction And Hypothesis: Recent publications describe pigmentary changes in the retina associated with the use of pentosan polysulfate sodium, the only FDA-approved oral agent for relief of bladder pain or...
9.
Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
Nadeau Nguyen M, Reyes M, Jones S
JAMA Dermatol . 2021 Sep; 157(10):1237-1239. PMID: 34495281
No abstract available.
10.
Cisplatin-Associated Aortic Thrombosis: A Review of Cases Reported to the FDA Adverse Event Reporting System
Nadeau Nguyen M, Woronow D, Binks B, Nayernama A, Jones S
JACC CardioOncol . 2021 Aug; 3(1):165. PMID: 34396320
No abstract available.